December 21, 2015
Findings also show how an experimental monoclonal antibody treatment inhibits growth and spread of cancer —
Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the most common form of blood cancer in adults.
They note, however, that these effects of Wnt5a were blocked by a humanized monoclonal antibody specific for ROR1, called cirmtuzumab (or UC-961), which inhibited the growth and spread of CLL cells in both cell lines and mouse models of leukemia. The findings are published in the December 21, 2015 issue of The Journal of Clinical Investigation. … Read the full story from the UC San Diego Newsroom
Thomas J. Kipps, MD, PhD, senior author of the study report, is Evelyn and Edwin Tasch Chair in Cancer Research and deputy director for research at Moores Cancer Center. He is Professor of Medicine in the Divisions of Hematology-Oncology and Bone Marrow Transplantation.